INSIGHTS ON SOLID DOSE MANUFACTURING

• Integration From Formulation Development To Manufacturing, Packaging

  Adare Pharma Solutions' Pessano, Italy facility offers 220,000 sq. ft. of end-to-end services, including R&D, formulation development, clinical and commercial manufacturing, packaging, and advanced analytical capabilities.

• The Future Of Oral Solid Dose Development And Innovation

  Tom Sellig, CEO of Adare, discusses the ongoing relevance of small molecules, oral solid dose development, trends like GLP-1, and innovations like 3D printing in pharmaceuticals.

• Future Of Pharma Packaging: Trends, Tech, And Patient Solutions

  Explore how traditional and innovative pharmaceutical packaging formats improve patient adherence, support emerging therapies, and shape the future of drug delivery and treatment outcomes.

• When To Consider Material And Personnel Airlocks For Downflow Booths

  Strategic use of airlocks in downflow booth design enhances pressure stability and containment. A risk-based approach ensures facility integration meets rigorous safety and compliance standards.

• Optimising Solubility: Selecting The Right Technology For Early Drug Development

  5/6/2026

  Discover how selecting the right solubility‑enhancing technology improves early exposure, supports flexible dosing, and lays a strong foundation for downstream oral drug development.

• Maximize Uptime And Yield With This Feeder Base Leveling System

  10/8/2025

  Learn how a patented leveling system provides real-time, three-gauge feedback, ensuring precision, maximizing uptime, and protecting your critical production equipment.

• The Role Of Quality By Design In Pharmaceutical Tablet Development

  7/30/2024

  Quality by Design (QbD) ensures efficiency and high standards in pharmaceutical tablet development. Explore how this proactive approach transforms manufacturing processes and enhances product quality.

• How To Handle Intrinsic Product Powder Particles

  3/16/2026

  Powder filling creates intrinsic particles that interfere with continuous monitoring. Risk‑based strategies must separate product dust from true contamination to meet Annex 1 requirements.

• High Potency APIs And The Evolving Demands Of Drug Development

  4/13/2026

  See how higher API activity is changing expectations around containment, scalability, and cross‑functional alignment — and why early decisions now have a greater impact on long‑term success.